Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer

Pridvi Kandagatla; Natalie N. Rizk; Danijela Dokic; Jeannie Kochkodan; Samantha Estevez; Megan Yanik; Sowmya Goranta; Kathryn Huber-Keener; Jacqueline S. Jeruss

doi:10.1111/tbj.13528

Back

Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer

Journal article

Open access

Peer reviewed

Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer

Pridvi Kandagatla, Natalie N. Rizk, Danijela Dokic, Jeannie Kochkodan, Samantha Estevez, Megan Yanik, Sowmya Goranta, Kathryn Huber-Keener and Jacqueline S. Jeruss

The breast journal, Vol.26(3), pp.464-468

03/01/2020

DOI: 10.1111/tbj.13528

PMCID: PMC10167625

PMID: 31538708

Files and links (1)

url

https://doi.org/10.1111/tbj.13528View

Published (Version of record) Open Access

Abstract

We sought to identify factors associated with disparities in tamoxifen utilization among young patients at high-risk for developing breast cancer. We identified 67 premenopausal, high-risk women age 35-45, without surgical prophylaxis, who did not initiate tamoxifen. Factors associated with noninitiation were examined. About 37% of patients had no documented provider-based discussion regarding initiation. Type of high-risk diagnosis was the only factor associated with a provider-based discussion (P = .03). For patients offered tamoxifen, primary reasons for noninitiation were perceived minimal benefit (66.7%), fertility concerns (16.7%), and concerns about side effects (7.1%). Implementation of comprehensive educational strategies regarding the benefits of tamoxifen should be facilitated to improve initiation among young high-risk patients.

Life Sciences & Biomedicine

Obstetrics & Gynecology

Oncology

Science & Technology

Details

Title: Subtitle: Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer
Creators: Pridvi Kandagatla - Henry Ford Hospital
Natalie N. Rizk - University of Michigan–Ann Arbor
Danijela Dokic - Mercy Hospital and Medical Center
Jeannie Kochkodan - University of Michigan–Ann Arbor
Samantha Estevez - Ob/Gyn, Zucker School of Medicine, Hempstead, New York.
Megan Yanik - University of Michigan–Ann Arbor
Sowmya Goranta - Michigan State University
Kathryn Huber-Keener - University of Iowa
Jacqueline S. Jeruss - University of Michigan–Ann Arbor
Resource Type: Journal article
Publication Details: The breast journal, Vol.26(3), pp.464-468
DOI: 10.1111/tbj.13528
PMID: 31538708
PMCID: PMC10167625
NLM abbreviation: Breast J
ISSN: 1075-122X
eISSN: 1524-4741
Publisher: Wiley
Number of pages: 5
Grant note: Stichting A Sister's Hope R01CA214384; T32CA009672 / National Institute of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
Language: English
Date published: 03/01/2020
Academic Unit: Obstetrics and Gynecology
Record Identifier: 9984318226602771

Metrics

5 Record Views

2 Times Cited - Web of Science